2,388 results on '"van Bodegraven, A. A."'
Search Results
2. Nationwide validation of the distal fistula risk score (D-FRS)
- Author
-
van Bodegraven, Eduard A., den Haring, Femke E. T., Pollemans, Britt, Monselis, Damaris, De Pastena, Matteo, van Eijck, Casper, Daams, Freek, de Hingh, Ignace, Luyer, Misha, Stommel, Martijn W. J., van Santvoort, Hjalmar C., Festen, S., Mieog, J. S. D., Klaase, J., Lips, D., Coolsen, M. M. E., van der Schelling, G. P., Manusama, E. R., Patijn, G., van der Harst, E., Bosscha, K., Marchegiani, Giovanni, and Besselink, Marc G.
- Published
- 2024
- Full Text
- View/download PDF
3. A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial
- Author
-
van Linschoten, Reinier C. A., Jansen, Fenna M., Pauwels, Renske W. M., Smits, Lisa J. T., Atsma, Femke, Kievit, Wietske, de Jong, Dirk J., de Vries, Annemarie C., Boekema, Paul J., West, Rachel L., Bodelier, Alexander G. L., Gisbertz, Ingrid A. M., Wolfhagen, Frank H. J., Römkens, Tessa E. H., Lutgens, Maurice W. M. D., van Bodegraven, Adriaan A., Oldenburg, Bas, Pierik, Marieke J., Russel, Maurice G. V. M., de Boer, Nanne K., Mallant-Hent, Rosalie C., ter Borg, Pieter C. J., van der Meulen-de Jong, Andrea E., Jansen, Jeroen M., Jansen, Sita V., Tan, Adrianus C. I. T. L., van der Woude, C. Janneke, and Hoentjen, Frank
- Published
- 2024
- Full Text
- View/download PDF
4. Tailoring the Use of Central Pancreatectomy Through Prediction Models for Major Morbidity and Postoperative Diabetes: International Retrospective Multicenter Study
- Author
-
van Bodegraven, Eduard Antonie, Lof, Sanne, Jones, Leia, Aussilhou, Béatrice, Yong, Gao, Jishu, Wei, Klotz, Rosa, Rocha-Castellanos, Dario Missael, Matsumato, Ippei, de Ponthaud, Charles, Tanaka, Kimitaka, Biesel, Esther, Kauffmann, Emmanuele, Dumitrascu, Traian, Nagakawa, Yuichi, Martí-Cruchaga, Pablo, Roeyen, Geert, Zerbi, Alessandro, Goetz, Mara, de Meijer, Vincent E., Pessaux, Patrick, Ignatavicius, Povilas, Demir, Ihsan Ekin, Giuffrida, Mario, Tingstedt, Bobby, Marino, Marco Vito, Mastoridis, Sotiris, Brunner, Maximilian, Mora-Oliver, Isabel, Bortolato, Cecilia, Gulla, Aisté, Apers, Thomas, Hermand, Hélène, Mitsuka, Yusuke, Popescu, Irinel, Boggi, Ugo, Wittel, Uwe, Hirano, Satoshi, Gaujoux, Sébastien, Kamei, Keiko, Fernández-Del Castillo, Carlos, Hackert, Thilo, Kuirong, Jiang, Yi, Miao, Sauvanet, Alain, Besselink, Marc, Abu Hilal, Mohammad, and Dokmak, Safi
- Published
- 2024
- Full Text
- View/download PDF
5. Neovaginal cancer after sigmoid vaginoplasty: Implications for postoperative cancer surveillance
- Author
-
Wouter B. van der Sluis, Nanne K.H. de Boer, Marlon E. Buncamper, Adriaan A. van Bodegraven, Jurriaan B. Tuynman, and Mark-Bram Bouman
- Subjects
Intestinal vaginoplasty ,Sigmoid vaginoplasty ,Cancer ,Neovagina ,Transgender ,Surgery ,RD1-811 - Abstract
Background: Intestinal vaginoplasty can be performed as vaginal reconstruction procedure. Aa pedicled intestinal segment is isolated and transferred to the (neo)vaginal cavity to form the neovaginal lining. Case: A 38-year old patient with Fanconi anemia and congenital vaginal absence, who underwent sigmoid vaginoplasty at the age of one, visited the outpatient clinic with a palpable neovaginal mass. At MRI examination, a neovaginal tumor was observed of approximately 25 × 10 mm without lymphadenopathy, which turned out to be a mucinous adenocarcinoma (T3N0M0). She underwent excision of the total mesocolon, including the sigmoid neovagina, coloanal anastomosis and anus. Summary and Conclusion: Postoperative cancer surveillance seems justified after sigmoid vaginoplasty, even more so in patients with a (genetically) high risk of developing cancer and/or with a history of malignancy.
- Published
- 2024
- Full Text
- View/download PDF
6. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study
- Author
-
Michalski, C.W., de Wilde, R.F., Tufekci, T., Ishida, H., Dennahy, I.S., Carter, J.A., Olapo, J.S., Caldera, M., Mazzola, M., Oshima, M., Tanaka, N., Choi, S.H., Sato, S., Sugawara, S., Abadia-Forcen, T., Pawlik, T.M., Kimura, Y., Rangelova, E., Stoop, T.F., van Ramshorst, T.M.E., Ali, M., van Bodegraven, E.A., Javed, A.A., Hashimoto, D., Steyerberg, E., Banerjee, A., Jain, A., Sauvanet, A., Serrablo, A., Giani, A., Giardino, A., Zerbi, A., Arshad, A., Wijma, A.G., Coratti, A., Zironda, A., Socratous, A., Rojas, A., Halimi, A., Ejaz, A., Oba, A., Patel, B.Y., Björnsson, B., Reames, B.N., Tingstedt, B., Goh, B.K.P., Payá-Llorente, C., Del Pozo, C.D., González-Abós, C., Medin, C., van Eijck, C.H.J., de Ponthaud, C., Takishita, C., Schwabl, C., Månsson, C., Ricci, C., Thiels, C.A., Douchi, D., Hughes, D.L., Kilburn, D., Flanking, D., Kleive, D., Silva, D.S., Edil, B.H., Pando, E., Moltzer, E., Kauffman, E.F., Warren, E., Bozkurt, E., Sparrelid, E., Thoma, E., Verkolf, E., Ausania, F., Giannone, F., Hüttner, F.J., Burdio, F., Souche, F.R., Berrevoet, F., Daams, F., Motoi, F., Saliba, G., Kazemier, G., Roeyen, G., Nappo, G., Butturini, G., Ferrari, G., Kito Fusai, G., Honda, G., Sergeant, G., Karteszi, H., Takami, H., Suto, H., Matsumoto, I., Mora-Oliver, I., Frigerio, I., Fabre, J.M., Chen, J., Sham, J.G., Davide, J., Urdzik, J., de Martino, J., Nielsen, K., Okano, K., Kamei, K., Okada, K., Tanaka, K., Labori, K.J., Goodsell, K.E., Alberici, L., Webber, L., Kirkov, L., de Franco, L., Miyashita, M., Maglione, M., Gramellini, M., Ramera, M., Amaral, M.J., Ramaekers, M., Truty, M.J., van Dam, M.A., Stommel, M.W.J., Petrikowski, M., Imamura, M., Hayashi, M., D’Hondt, M., Brunner, M., Hogg, M.E., Zhang, C., Suárez-Muñoz, M.Á., Luyer, M.D., Unno, M., Mizuma, M., Janot, M., Sahakyan, M.A., Jamieson, N.B., Busch, O.R., Bilge, O., Belyaev, O., Franklin, O., Sánchez-Velázquez, P., Pessaux, P., Holka, P.S., Ghorbani, P., Casadei, R., Sartoris, R., Schulick, R.D., Grützmann, R., Sutcliffe, R., Mata, R., Patel, R.B., Takahashi, R., Franco, S.R., Cabús, S.S., Hirano, S., Gaujoux, S., Festen, S., Kozono, S., Maithel, S.K., Chai, S.M., Yamaki, S., van Laarhoven, S., Mieog, J.S.D., Murakami, T., Codjia, T., Sumiyoshi, T., Karsten, T.M., Nakamura, T., Sugawara, T., Boggi, U., Hartman, V., de Meijer, V.E., Bartholomä, W., Kwon, W., Koh, Y.X., Cho, Y., Takeyama, Y., Inoue, Y., Nagakawa, Y., Kawamoto, Y., Ome, Y., Soonawalla, Z., Uemura, K., Wolfgang, C.L., Jang, J.Y., Padbury, R., Satoi, S., Messersmith, W., Wilmink, J.W., Hila, M.A., Besselink, M.G., and Del Chiaro, M.
- Published
- 2025
- Full Text
- View/download PDF
7. Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease
- Author
-
van Bodegraven, Adriaan A., Fidder, Herma H., Hirdes, Meike M.C., Hoentjen, Frank, Jansen, Jeroen M., Mahmmod, Nofel, van der Meulen-de Jong, Andrea E., Ponsioen, Cyriel Y., van Schaik, Fiona D.M., van der Woude, C. Janneke, Wijnands, Anouk M., Penning de Vries, Bas B.L., Lutgens, Maurice W.M.D., Bakhshi, Zeinab, Al Bakir, Ibrahim, Beaugerie, Laurent, Bernstein, Charles N., Chang-ho Choi, Ryan, Coelho-Prabhu, Nayantara, Graham, Trevor A., Hart, Ailsa L., ten Hove, Joren R., Itzkowitz, Steven H., Kirchgesner, Julien, Mooiweer, Erik, Shaffer, Seth R., Shah, Shailja C., Elias, Sjoerd G., and Oldenburg, Bas
- Published
- 2024
- Full Text
- View/download PDF
8. Safety and performance of a synthetic sealant patch aimed to prevent postoperative pancreatic fistula after distal pancreatectomy (SHIELDS) – Prospective international multicenter phase II study
- Author
-
Goetz, Mara R., Heumann, Asmus, Bassi, Claudio, Landoni, Luca, Khatib-Chahidi, Karl, Ghadimi, Michael, von Heessen, Maximillian, Berrevoet, Frederik, Gryspeerdt, Filip, Besselink, Marc, van Bodegraven, Eduard A., Adham, Mustapha, Pratschke, Johann, Schöning, Wenzel, Izbicki, Jakob R., and Bockhorn, Maximilian
- Published
- 2024
- Full Text
- View/download PDF
9. Prophylactic abdominal drainage after distal pancreatectomy (PANDORINA): an international, multicentre, open-label, randomised controlled, non-inferiority trial
- Author
-
van Bodegraven, Eduard A, Balduzzi, Alberto, van Ramshorst, Tess M E, Malleo, Giuseppe, Vissers, Frederique L, van Hilst, Jony, Festen, Sebastiaan, Abu Hilal, Mohammad, Asbun, Horacio J, Michiels, Nynke, Koerkamp, Bas Groot, Busch, Olivier R C, Daams, Freek, Luyer, Misha D P, Ramera, Marco, Marchegiani, Giovanni, Klaase, Joost M, Molenaar, I Quintus, de Pastena, Matteo, Lionetto, Gabriella, Vacca, Pier Giuseppe, van Santvoort, Hjalmar C, Stommel, Martijn W J, Lips, Daan J, Coolsen, Mariëlle M E, Mieog, J Sven D, Salvia, Roberto, van Eijck, Casper H J, and Besselink, Marc G
- Published
- 2024
- Full Text
- View/download PDF
10. GFAP-isoforms in the nervous system: Understanding the need for diversity
- Author
-
de Reus, Alexandra J.E.M., Basak, Onur, Dykstra, Werner, van Asperen, Jessy V., van Bodegraven, Emma J., and Hol, Elly M.
- Published
- 2024
- Full Text
- View/download PDF
11. Correction: Prophylactic abdominal drainage or no drainage after distal pancreatectomy (PANDORINA): a study protocol of a binational multicenter randomized controlled trial
- Author
-
Vissers, F. L., Balduzzi, A., van Bodegraven, E. A., van Hilst, J., Festen, S., Hilal, M. Abu, Asbun, H. J., Mieog, J. S. D., Koerkamp, B. Groot, Busch, O. R., Daams, F., Luyer, M., De Pastena, M., Malleo, G., Marchegiani, G., Klaase, J., Molenaar, I. Q., Salvia, R., van Santvoort, H. C., Stommel, M., Lips, D., Coolsen, M., Bassi, C., van Eijck, C., and Besselink, M. G.
- Published
- 2023
- Full Text
- View/download PDF
12. Short bowel syndrome, intestinaal falen en intestinale insufficiëntie
- Author
-
van Bodegraven, Ad, Wierdsma, Nicolette, Soeters, Maarten, editor, Wierdsma, Nicolette, editor, Kruizenga, Hinke, editor, and Bouma, Gerd, editor
- Published
- 2023
- Full Text
- View/download PDF
13. Anatomie en functie van de tractus digestivus
- Author
-
van Bodegraven, Ad, Soeters, Maarten, editor, Wierdsma, Nicolette, editor, Kruizenga, Hinke, editor, and Bouma, Gerd, editor
- Published
- 2023
- Full Text
- View/download PDF
14. Effects of processed meat and drinking water nitrate on oral and fecal microbial populations in a controlled feeding study
- Author
-
Sinha, Rashmi, Zhao, Ni, Goedert, James J, Byrd, Doratha A, Wan, Yunhu, Hua, Xing, Hullings, Autumn G, Knight, Rob, van Breda, Simone, Mathijs, Karen, de Kok, Theo M, Ward, Mary H, members, PHYTOME consortium, Pieters, Harm-Jan, Sági-Kiss, Virág, Kuhnle, Gunter G, Georgiadis, Panagiotis, Saccani, Giovanna, Parolari, Giovanni, Virgili, Roberta, Hemke, Gert, Hung, Yung, Verbeke, Wim, Masclee, Ad A, Vleugels-Simon, Carla B, van Bodegraven, Adriaan A, Dobbelaere, Dirk, Vandewynkel, Anneleen, van der Kruijk, Richard, Egberts, Frans, and van Helvoirt, Jan-Hein
- Subjects
Biological Sciences ,Environmental Sciences ,Chemical Sciences ,Digestive Diseases ,Nutrition ,Cancer ,Oral and gastrointestinal ,Diet ,Drinking Water ,Humans ,Meat ,Nitrates ,Nitrites ,RNA ,Ribosomal ,16S ,Processed meat ,Water nitrate ,Nitrite ,Oral and fecal microbiome ,Phytochemicals ,PHYTOME consortium members ,Toxicology ,Biological sciences ,Chemical sciences ,Environmental sciences - Abstract
BackgroundOne mechanism that can explain the link between processed meat consumption and colorectal cancer (CRC) is the production of carcinogenic N-nitroso compounds (NOCs) in the gastrointestinal tract. Oral and gut microbes metabolize ingested proteins (a source of secondary and tertiary amines and amides) and can reduce nitrate to nitrite, generating potentially carcinogenic NOCs.ObjectiveWe evaluated whether nitrate/nitrite in processed meat or water influences the fecal or salivary microbiota.DesignIn this dietary intervention study, 63 volunteers consumed diets high in conventional processed meats for two weeks, switched to diets high in poultry for two weeks, and then consumed phytochemical-enriched conventional processed or low-nitrite processed meat diets for two weeks. During the intervention, they drank water with low nitrate concentrations and consumed a healthy diet with low antioxidants. Then the volunteers drank nitrate-enriched water for 1 week, in combination with one of the four different diets. We measured creatinine-adjusted urinary nitrate levels and characterized the oral and fecal microbiota using 16S rRNA amplicon sequencing.ResultsUsing linear mixed models, we found that, compared to baseline, urinary nitrate levels were reduced during the phytochemical-enriched low-nitrite meat diet (p-value = 0.009) and modestly during the poultry diet (p-value = 0.048). In contrast, urinary nitrate increased after 1-week of drinking nitrate-enriched water (p-value
- Published
- 2021
15. An evaluation of antibiotic prescribing trends and their impact on infection-related complications in primary- and secondary care in the UK
- Author
-
Van Bodegraven, Birgitta, Palin, Victoria, Sperrin, Matthew, and Van Staa, Tjeerd
- Subjects
Complication ,Respiratory tract infection ,Adverse event ,Targeted prescribing ,Urinary tract infection ,Infection ,Antibiotic ,General practitioner ,Primary care - Abstract
The majority of antibiotics (approximately 80%) are prescribed by general practitioners (GPs) in the UK. Reducing inappropriate antibiotic prescribing is an important aim of antibiotic stewardship programmes (ASP) in order to maintain the efficacy of existing antibiotics for future generations. Analysis of longitudinal data from research databases in the UK including CPRD, SAIL Databank, and NHS digital open prescribing, can provide an insight into the effectiveness of current interventions, reports and guidelines aimed at reducing inappropriate prescribing. The aim of this thesis was to evaluate factors influencing antibiotic prescribing in primary care in the UK at patient- and practice level. Broadly, three research questions were considered: (1) To what extent does varying antibiotic prescribing for common infections influence infection-related complications? (2) Are patient characteristics and risk factors being used to inform antibiotic prescribing? (3) Are there any consistent antibiotic prescribing trends among English GPs and what factors influence this? Chapter 2 found the effect of physician preference antibiotic prescribing on the risk of infection-related complications among antibiotic users compared with non-antibiotics users. Chapter 3 demonstrates an inverse association between lower levels of practice level antibiotic prescribing for common infections and higher rates of infection-related complications by comparing high and low prescribing GP practices. In Chapter 4, this association was further explored and showed a large variability in absolute risk reductions for patients with an incidental common infection and an independence of predicted risk with GPs propensity to prescribe antibiotics. While Chapters 2-4 present the effect of antibiotic prescribing on infection-related complications for patients in primary care (RQ1/RQ2). These analyses do not provide insight into antibiotic changes through time and the potential of identifying GP practices for targeted antibiotic guidance. Thus, Chapter 5 explored the complex heterogeneity of antibiotic prescribing trends among English GPs and identified seven clusters with similar prescribing trends over time, which were not associated with deprivation scores (RQ3). Notable changes in prescribing trend were detected in early 2015, mid 2016, and late 2017. This thesis has the potential to improve understanding of the potential effects of reduced antibiotic prescribing in primary care and inform the implementation of more targeted identification of GPs and patients who will benefit most from a fundamental change in antibiotic prescribing behaviour.
- Published
- 2021
16. Costs of complications following distal pancreatectomy: a systematic review
- Author
-
van Bodegraven, Eduard A., Francken, Michiel F.G., Verkoulen, Koen C.H.A., Abu Hilal, Mohammad, Dijkgraaf, Marcel G.W., and Besselink, Marc G.
- Published
- 2023
- Full Text
- View/download PDF
17. Robot-assisted versus laparoscopic distal pancreatectomy: a systematic review and meta-analysis including patient subgroups
- Author
-
van Ramshorst, Tess M. E., van Bodegraven, Eduard A., Zampedri, Pietro, Kasai, Meidai, Besselink, Marc G., and Abu Hilal, Mohammad
- Published
- 2023
- Full Text
- View/download PDF
18. The Brescia Internationally Validated European Guidelines on Minimally Invasive Pancreatic Surgery (EGUMIPS)
- Author
-
Abu Hilal, Mohammad, van Ramshorst, Tess M.E., Boggi, Ugo, Dokmak, Safi, Edwin, Bjørn, Keck, Tobias, Khatkov, Igor, Ahmad, Jawad, Al Saati, Hani, Alseidi, Adnan, Azagra, Juan S., Björnsson, Bergthor, Can, Fatih M., D’Hondt, Mathieu, Efanov, Mikhail, Espin Alvarez, Francisco, Esposito, Alessandro, Ferrari, Giovanni, Groot Koerkamp, Bas, Gumbs, Andrew A., Hogg, Melissa E., Huscher, Cristiano G.S., Ielpo, Benedetto, Ivanecz, Arpad, Jang, Jin-Young, Liu, Rong, Luyer, Misha D.P., Menon, Krishna, Nakamura, Masafumi, Piardi, Tullio, Saint-Marc, Olivier, White, Steve, Yoon, Yoo-Seok, Zerbi, Alessandro, Bassi, Claudio, Berrevoet, Frederik, Chan, Carlos, Coimbra, Felipe J., Conlon, Kevin C.P., Cook, Andrew, Dervenis, Christos, Falconi, Massimo, Ferrari, Clarissa, Frigerio, Isabella, Fusai, Giuseppe K., De Oliveira, Michelle L., Pinna, Antonio D., Primrose, John N., Sauvanet, Alain, Serrablo, Alejandro, Smadi, Sameer, Badran, Ali, Baychorov, Magomet, Bannone, Elisa, van Bodegraven, Eduard A., Emmen, Anouk M.L.H., Giani, Alessandro, de Graaf, Nine, van Hilst, Jony, Jones, Leia R., Levi Sandri, Giovanni B., Pulvirenti, Alessandra, Ramera, Marco, Rashidian, Niki, Sahakyan, Mushegh A., Uijterwijk, Bas A., Zampedri, Pietro, Zwart, Maurice J.W., Alfieri, Sergio, Berti, Stefano, Butturini, Giovanni, Di Benedetto, Fabrizio, Ettorre, Giuseppe M., Giuliante, Felice, Jovine, Elio, Memeo, Riccardo, Portolani, Nazario, Ruzzenente, Andrea, Salvia, Roberto, Siriwardena, Ajith K., Besselink, Marc G., Asbun, Horacio J., Over, Paul, Saleh, Omar, and Rivizzigno, Piero
- Published
- 2024
- Full Text
- View/download PDF
19. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial
- Author
-
van Noord, Desirée, Hoekstra, Jildou, Kamphuis, Johannes T., Gorter, Moniek H.P., van Esch, Aura A.J., van Linschoten, Reinier C A, Jansen, Fenna M, Pauwels, Renske W M, Smits, Lisa J T, Atsma, Femke, Kievit, Wietske, de Jong, Dirk J, de Vries, Annemarie C, Boekema, Paul J, West, Rachel L, Bodelier, Alexander G L, Gisbertz, Ingrid A M, Wolfhagen, Frank H J, Römkens, Tessa E H, Lutgens, Maurice W M D, van Bodegraven, Adriaan A, Oldenburg, Bas, Pierik, Marieke J, Russel, Maurice G V M, de Boer, Nanne K, Mallant-Hent, Rosalie C, ter Borg, Pieter C J, van der Meulen-de Jong, Andrea E, Jansen, Jeroen M, Jansen, Sita V, Tan, Adrianus C I T L, van der Woude, C Janneke, and Hoentjen, Frank
- Published
- 2023
- Full Text
- View/download PDF
20. Limited honeybee hive placement balances the trade-off between biodiversity conservation and crop yield of buckwheat cultivation
- Author
-
Thijs P.M. Fijen, Vincent van Bodegraven, and Fieke Lucassen
- Subjects
Crop pollination ,Pollinator management ,Resource competition ,Nature-inclusive farming ,Buckwheat Fagopyrum esculentum ,Biodiversity conservation ,Ecology ,QH540-549.5 - Abstract
An increasing number of farmland initiatives aim to aid biodiversity conservation through alternative farming practices such as nature-inclusive farming. However, these approaches frequently lead to trade-offs between biodiversity conservation and crop yield. For example, buckwheat (Fagopyrum esculentum) is a melliferous crop that flowers for a long period in the summer when nectar in agricultural areas is generally scarce, and buckwheat cultivation could therefore contribute to wild pollinator conservation. However, honeybees (Apis mellifera) are placed to ensure sufficient crop pollination, which potentially increases resource competition with wild pollinators in and around the crop. Here, we have studied this trade-off by surveying pollinators in and around 16 small-scale (∼1 ha) flowering buckwheat fields and we determined the contribution of pollinator density to crop yield in a nature-inclusive farming project. We found that the buckwheat pollinator community was diverse, albeit dominated by honeybees. We found no clear indications of resource competition between honeybees and wild pollinators within the buckwheat fields. Honeybee density in the surroundings was generally low, and increased minimally during honeybee-hive placement. While densities of honeybees decreased non-linearly over the day in buckwheat fields, they did not (temporarily) move into the surroundings of the field, suggesting limited competition for resources with wild pollinators. Crop yield was largely dependent on crop pollinator density, notably of honeybees, and to a lesser extent crop biomass (as a proxy for agricultural management). Our results show that buckwheat cultivation fits well within nature-inclusive farming if some simple precautionary measures are being taken, such as limiting the honeybee-hive densities and placing hives only during the main flowering period. The introduction of buckwheat cultivation into crop rotation could then contribute to fill an important nectar gap in the summer, which potentially boosts wild pollinator populations in the long term.
- Published
- 2022
- Full Text
- View/download PDF
21. PDE-Constrained Optimization for Nuclear Mechanics.
- Author
-
Yekta Kesenci, Aleix Boquet-Pujadas, Emma van Bodegraven, Sandrine étienne-Manneville, Elisabeth Labruyère, and Jean-Christophe Olivo-Marin
- Published
- 2022
- Full Text
- View/download PDF
22. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study
- Author
-
Schlotter, Malena, van Workum, Martine, de Jong, Dirk, van Dop, Willemijn, van der Marel, S., El Ghabzouri, Hayat, Talhaoui, Kamila, Oldenburg, Bas, Boontje, Nynke, Fidder, Herma, Hirdes, Meike, Creemers, Rob H., Hoekstra, J., Smid, Jael, Mujagic, Zlatan, François-Verweij, Marthe, Schakel- van den Berge, Toos, Maljaars, Jeroen, Theeuwen, Rosaline, van den Berg, Denise, Gerretsen, Suzanne, Yocarini, Xenia, D’Haens, Geert, Lowenberg, Mark, Grootjans, Joep, Gecse, Krisztina, Bouma, Gerd, Waaijenberg, Petra, Muskens, Bart, Straatmijer, Tessa, Biemans, Vince B.C., Visschedijk, Marijn, Hoentjen, Frank, de Vries, Annemarie, van Bodegraven, Adriaan A., Bodelier, Alexander, de Boer, Nanne K.H., Dijkstra, Gerard, Festen, Noortje, Horjus, Carmen, Jansen, Jeroen M., Jharap, Bindia, Mares, Wout, van Schaik, Fiona D.M., Ponsioen, Cyriel, Romkens, Tessa, Srivastava, Nidhi, van der Voorn, Michael M.P. J.A., West, Rachel, van der Woude, Janneke, Wolvers, Marije D.J., Pierik, Marieke, van der Meulen-de Jong, Andrea E., and Duijvestein, Marjolijn
- Published
- 2023
- Full Text
- View/download PDF
23. A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patients
- Author
-
Debbie S. Deben, Rob H. Creemers, Arjan J. van Adrichem, Roosmarie Drent, Audrey H. H. Merry, Mathie P. G. Leers, Adriaan A. van Bodegraven, and Dennis R. Wong
- Subjects
Medicine ,Science - Abstract
Abstract The thiopurine derivatives azathioprine (AZA), mercaptopurine (MP) and tioguanine (TG) remain standard treatment of inflammatory bowel disease (IBD). The immune suppressive effect of thiopurines is primarily based on blocking the Ras-related C3 botulinum toxin substrate 1 (Rac1) causing apoptosis of T lymphocytes by inhibition of the phosphorylated downstream transcription factor Signal Transducer and Activator of Transcription 3 (pSTAT3). A functional pharmacodynamic marker in T lymphocytes may be useful to predict therapeutic outcome of thiopurine therapy. The aim of this study was to explore whether protein levels of Rac1 and pSTAT3 in T lymphocytes may be applied as a specific pharmacodynamic marker for thiopurine therapy in IBD patients. Rac1 and pSTAT3 protein levels in T lymphocytes were explored in 57 IBD patients (median age 51 years, 56% female), subdivided into six groups based on IBD activity and its treatment: patients with active disease without IBD maintenance medication (1) or patients in remission on AZA/MP (2), TG (3), infliximab (IFX) (4), thiopurine and IFX combination-treatment (5) or without IBD medication (6). Reference values were obtained from healthy subjects. Rac1 and pSTAT3 protein levels in T lymphocytes from patients on thiopurine monotherapy (group 2 and 3) were compared to the other groups, and to healthy subjects. Absolute Rac1 and pSTAT3 protein levels showed no differences between the thiopurine monotherapy groups when compared to patients with active disease. However, the ratio of Rac1 and pSTAT3 protein levels was lower in thiopurine patients groups compared to patients with active disease. Rac1-corrected pSTAT3 protein levels may serve as a pharmacodynamic marker of thiopurine monotherapy and may be a potential tool to predict therapeutic effectiveness in IBD patients.
- Published
- 2022
- Full Text
- View/download PDF
24. Prophylactic abdominal drainage or no drainage after distal pancreatectomy (PANDORINA): a study protocol of a binational multicenter randomized controlled trial
- Author
-
F. L. Vissers, A. Balduzzi, E. A. van Bodegraven, J. van Hilst, S. Festen, M. Abu Hilal, H. J. Asbun, J. S. D. Mieog, B. Groot Koerkamp, O. R. Busch, F. Daams, M. Luyer, M. De Pastena, G. Malleo, G. Marchegiani, J. Klaase, I. Q. Molenaar, R. Salvia, H. C. van Santvoort, M. Stommel, D. Lips, M. Coolsen, C. Bassi, C. van Eijck, M. G. Besselink, and for the Dutch Pancreatic Cancer Group
- Subjects
Medicine (General) ,R5-920 - Abstract
Abstract Background Prophylactic abdominal drainage is current standard practice after distal pancreatectomy (DP), with the aim to divert pancreatic fluid in case of a postoperative pancreatic fistula (POPF) aimed to prevent further complications as bleeding. Whereas POPF after pancreatoduodenectomy, by definition, involves infection due to anastomotic dehiscence, a POPF after DP is essentially sterile since the bowel is not opened and no anastomoses are created. Routine drainage after DP could potentially be omitted and this could even be beneficial because of the hypothetical prevention of drain-induced infections (Fisher, 2018). Abdominal drainage, moreover, should only be performed if it provides additional safety or comfort to the patient. In clinical practice, drains cause clear discomfort. One multicenter randomized controlled trial confirmed the safety of omitting abdominal drainage but did not stratify patients according to their risk of POPF and did not describe a standardized strategy for pancreatic transection. Therefore, a large pragmatic multicenter randomized controlled trial is required, with prespecified POPF risk groups and a homogeneous method of stump closure. The objective of the PANDORINA trial is to evaluate the non-inferiority of omitting routine intra-abdominal drainage after DP on postoperative morbidity (Clavien-Dindo score ≥ 3), and, secondarily, POPF grade B/C. Methods/design Binational multicenter randomized controlled non-inferiority trial, stratifying patients to high and low risk for POPF grade B/C and incorporating a standardized strategy for pancreatic transection. Two groups of 141 patients (282 in total) undergoing elective DP (either open or minimally invasive, with or without splenectomy). Primary outcome is postoperative rate of morbidity (Clavien-Dindo score ≥ 3), and the most relevant secondary outcome is grade B/C POPF. Other secondary outcomes include surgical reintervention, percutaneous catheter drainage, endoscopic catheter drainage, abdominal collections (not requiring drainage), wound infection, delayed gastric emptying, postpancreatectomy hemorrhage as defined by the international study group for pancreatic surgery (ISGPS) (Wente et al., 2007), length of stay (LOS), readmission within 90 days, in-hospital mortality, and 90-day mortality. Discussion PANDORINA is the first binational, multicenter, randomized controlled non-inferiority trial with the primary objective to evaluate the hypothesis that omitting prophylactic abdominal drainage after DP does not worsen the risk of postoperative severe complications (Wente et al., 2007; Bassi et al., 2017). Most of the published studies on drain placement after pancreatectomy focus on both pancreatoduodenectomy and DP, but these two entities present are associated with different complications and therefore deserve separate evaluation (McMillan et al., 2016; Pratt et al., 2006). The PANDORINA trial is innovative since it takes the preoperative risk on POPF into account based on the D-FRS and it warrants homogenous stump closing by using the same graded compression technique and same stapling device (de Pastena et al., 2022; Asbun and Stauffer, 2011).
- Published
- 2022
- Full Text
- View/download PDF
25. Minimally invasive versus open central pancreatectomy: Systematic review and meta-analysis
- Author
-
Farrarons, Sara Sentí, van Bodegraven, Eduard A., Sauvanet, Alain, Hilal, Mohammed Abu, Besselink, Marc G., and Dokmak, Safi
- Published
- 2022
- Full Text
- View/download PDF
26. Routine prophylactic abdominal drainage versus no-drain strategy after distal pancreatectomy: A multicenter propensity score matched analysis
- Author
-
van Bodegraven, Eduard A., De Pastena, Matteo, Vissers, Frederique L., Balduzzi, Alberto, Stauffer, John, Esposito, Alessandro, Malleo, Giuseppe, Marchegiani, Giovanni, Busch, Olivier R., Salvia, Roberto, van Hilst, Jony, Bassi, Claudio, Besselink, Marc G., and Asbun, Horacio J.
- Published
- 2022
- Full Text
- View/download PDF
27. Tailoring the Use of Central Pancreatectomy Through Prediction Models for Major Morbidity and Postoperative Diabetes: International Retrospective Multicenter Study.
- Author
-
Antonie van Bodegraven, Eduard, Lof, Sanne, Jones, Leia, Aussilhou, Béatrice, Gao Yong, Wei Jishu, Klotz, Rosa, Missael Rocha-Castellanos, Dario, Matsumato, Ippei, de Ponthaud, Charles, Tanaka, Kimitaka, Biesel, Esther, Kauffmann, Emmanuele, Dumitrascu, Traian, Yuichi Nagakawa, Martí-Cruchaga, Pablo, Roeyen, Geert, Zerbi, Alessandro, Goetz, Mara, and de Meijer, Vincent E.
- Abstract
Objective: To develop a prediction model for major morbidity and endocrine dysfunction after central pancreatectomy (CP) which could help in tailoring the use of this procedure. Background: CP is a parenchyma-sparing alternative to distal pancreatectomy for symptomatic benign and premalignant tumors in the body and neck of the pancreas CP lowers the risk of new-onset diabetes and exocrine pancreatic insufficiency compared with distal pancreatectomy but it is thought to increase the risk of short-term complications, including postoperative pancreatic fistula (POPF). Methods: International multicenter retrospective cohort study including patients from 51 centers in 19 countries (2010-2021). The primary endpoint was major morbidity. Secondary endpoints included POPF grade B/C, endocrine dysfunction, and the use of pancreatic enzymes. Two risk models were designed for major morbidity and endocrine dysfunction utilizing multivariable logistic regression and internal and external validation. Results: A total of 838 patients after CP were included [301 (36%) minimally invasive] and major morbidity occurred in 248 (30%) patients, POPF B/C in 365 (44%), and 30-day mortality in 4 (1%). Endocrine dysfunction in 91 patients (11%) and use of pancreatic enzymes in 108 (12%). The risk model for major morbidity included male sex, age, Body Mass Index, and American Society of Anesthesiologists score =3. The model performed acceptably with an area under the curve of 0.72 (CI: 0.68-0.76). The risk model for endocrine dysfunction included higher Body Mass Index and male sex and performed well [area under the curve: 0.83 (CI: 0.77-0.89)]. Conclusions: The proposed risk models help in tailoring the use of CP in patients with symptomatic benign and premalignant lesions in the body and neck of the pancreas (readily available through www. pancreascalculator.com). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment.
- Author
-
Deben, Debbie S., Winkens, Bjorn, van Moorsel, Sofia A. W., van Oijen, Brigit P. C., Bus, Paul, Pierik, Marieke J., Simsek, Melek, de Boer, Nanne K. H., Leers, Mathie P. G., Wong, Dennis R., and van Bodegraven, Adriaan A.
- Subjects
INFLAMMATORY bowel diseases ,DRUG monitoring ,DRUG side effects ,TERMINATION of treatment ,BODY mass index ,AZATHIOPRINE - Abstract
Aims: Conventional thiopurines (azathioprine and mercaptopurine) remain standard therapy to maintain steroid sparing remission in inflammatory bowel disease (IBD), but are regularly discontinued due to adverse drug reactions (ADRs). Measurement of the metabolites 6‐thioguanine nucleotides (6‐TGN), 6‐methylmercaptopurine ribonucleotides (6‐MMPR) and the 6‐MMPR/6‐TGN ratio, may predict the development of these ADRs. Our aim was to evaluate whether early thiopurine metabolite measurements were associated with clinical outcomes. Methods: A post‐hoc analysis was conducted of a multicentre, prospective, observational study on thiopurine‐induced hepatotoxicity. IBD patients who initiated thiopurine therapy were included and thiopurine metabolite concentrations were assessed after 7 days (±1) (T1). Patients were monitored for 12 weeks to document the occurrence of ADRs, early treatment discontinuation and effectiveness. Results: In total, 181 patients were evaluated. At T1, 6‐MMPR concentrations and 6‐TGN/6‐MMPR ratios were independently related to treatment discontinuation within 12 weeks after correction for sex, age and body mass index (BMI) (P =.034 and.002, respectively). The largest effects were observed for 6‐MMPR ≥3000 pmol/8 × 108 RBC and 6‐TGN/6‐MMPR ratio ≥17. Furthermore, 6‐MMPR concentrations and 6‐TGN/6‐MMPR ratios at T1 were independently related to skewed metabolism at steady state (Week 8, 6‐MMPR/‐6TGN ratio ≥11 and ≥20) (both P <.001). The occurrence of ADRs and effectiveness were not independently related to T1 thiopurine metabolite concentrations. Conclusions: Thiopurine metabolite concentrations at T1 were related to early treatment discontinuation and skewed metabolism at steady state, but not to effectiveness, helping to identify patients with a high risk of thiopurine treatment failure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Identification of spontaneous patient‐reported complaints related to perianal fistula in patients with Crohn's disease.
- Author
-
Bootsma, Lars, Vollebregt, Paul F., van Bodegraven, Adriaan A., van der Horst, Danielle, Han‐Geurts, Ingrid J. M., and Felt‐Bersma, Richelle J. F.
- Subjects
CROHN'S disease ,PATIENT reported outcome measures ,OLDER patients ,SEXUAL intercourse ,PSYCHOLOGICAL factors - Abstract
Aim: To identify patient‐reported complaints affecting quality of life in Crohn's disease patients with a perianal fistula, and to compare differences between subgroups. Method: A questionnaire was distributed to 1667 patients from the Dutch Crohn's and Colitis Patients' organization, those patients with Crohn's disease and perianal fistula were included. Patients were asked to report (using free text) their most important fistula‐related complaints affecting their quality of life. All responses were structurally analyzed and categorized. Data comparisons were made between subgroups: women versus men, patients with versus without current presence of a seton, and patients aged ≤40 versus >40 years. Results: Of 743 respondents (44.6%), 123 patients with Crohn's disease and perianal fistula were included (92 women, median age 41 years [IQR 34–56] and 36 with seton). A total of 776 complaints were allocated to 36 categories, with 19 reported in >10% of patients. Perianal fistula‐related complaints affected nearly all patients (95.9%). Impact on psychological status (71.7% vs. 29.0%; p < 0.0001) and on sexual activities (37.0% vs. 16.1%; p = 0.003) were more common in women than men. Younger patients more often reported insecurity (38.7% vs. 18.0%; p = 0.026), shame (29.0% vs. 11.5%; p = 0.024), and impact on sexual activities (40.3% vs. 23.0%; p = 0.048) than older patients. Patients with a seton more frequently reported self‐experienced malodour (50.0% vs. 23.0%; p = 0.005), physical activity limitations (41.7% vs. 19.5%; p = 0.014), and work/study impact (22.2% vs. 5.7%; p = 0.019). Conclusion: We identified 19 perianal fistula‐related complaints reported by >10% of patients. These complaints may guide improvement of current outcome measures. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. GFAP splice variants fine-tune glioma cell invasion and tumour dynamics by modulating migration persistence
- Author
-
Uceda-Castro, Rebeca, van Asperen, Jessy V., Vennin, Claire, Sluijs, Jacqueline A., van Bodegraven, Emma J., Margarido, Andreia S., Robe, Pierre A. J., van Rheenen, Jacco, and Hol, Elly M.
- Published
- 2022
- Full Text
- View/download PDF
31. Distal Pancreatectomy Fistula Risk Score (D-FRS): Development and International Validation
- Author
-
De Pastena, Matteo, van Bodegraven, Eduard A., Mungroop, Timothy H., Vissers, Frederique L., Jones, Leia R., Marchegiani, Giovanni, Balduzzi, Alberto, Klompmaker, Sjors, Paiella, Salvatore, Tavakoli Rad, Shazad, Groot Koerkamp, Bas, van Eijck, Casper, Busch, Olivier R., de Hingh, Ignace, Luyer, Misha, Barnhill, Caleb, Seykora, Thomas, Maxwell T, Trudeau, de Rooij, Thijs, Tuveri, Massimiliano, Malleo, Giuseppe, Esposito, Alessandro, Landoni, Luca, Casetti, Luca, Alseidi, Adnan, Salvia, Roberto, Steyerberg, Ewout W., Abu Hilal, Mohammad, Vollmer, Charles M., Besselink, Marc G., and Bassi, Claudio
- Published
- 2023
- Full Text
- View/download PDF
32. Determining glioma cell invasion and proliferation in ex vivo organotypic mouse brain slices using whole-mount immunostaining and tissue clearing
- Author
-
Jessy V. van Asperen, Emma J. van Bodegraven, Pierre A.J.T. Robe, and Elly M. Hol
- Subjects
Cell biology ,Cancer ,Microscopy ,Antibody ,Neuroscience ,Science (General) ,Q1-390 - Abstract
Summary: The ex vivo organotypic brain slice invasion model is commonly used to study the growth dynamics of gliomas, primary brain tumors that are known for their invasive behavior. Here, we describe a protocol where the ex vivo organotypic mouse brain slice invasion model is combined with whole-mount immunostaining, tissue clearing, and 3D reconstruction, to visualize and quantify the invasion of glioma cells. In addition, we describe an approach to determine the proliferation rate of the cells within this model.For complete details on the use and execution of this protocol, please refer to Uceda-Castro et al. (2022). : Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.
- Published
- 2022
- Full Text
- View/download PDF
33. Implications of Tioguanine Dosing in IBD Patients with a TPMT Deficiency
- Author
-
Debbie S. Deben, Luc J. J. Derijks, Bianca J. C. van den Bosch, Rob H. Creemers, Annick van Nunen, Adriaan A. van Bodegraven, and Dennis R. Wong
- Subjects
thiopurine S-methyl transferase (TPMT) ,tioguanine ,inflammatory bowel disease (IBD) ,TPMT deficiency ,Microbiology ,QR1-502 - Abstract
Tioguanine is metabolised by fewer enzymatic steps compared to azathioprine and mercaptopurine, without generating 6-methylmercaptopurine ribonucleotides. However, thiopurine S-methyl transferase (TPMT) plays a role in early toxicity in all thiopurines. We aimed to describe the hazards and opportunities of tioguanine use in inflammatory bowel disease (IBD) patients with aberrant TPMT metabolism and propose preventative measures to safely prescribe tioguanine in these patients. In this retrospective cohort study, all determined TPMT genotypes (2016–2021) were evaluated for aberrant metabolism (i.e., intermediate and poor TPMT metabolisers). Subsequently, all IBD patients on tioguanine with aberrant TPMT genotypes were evaluated for tioguanine dosages, adverse drug events, lab abnormalities, treatment duration and effectiveness. TPMT genotypes were determined in 485 patients, of whom, 50 (10.3%) and 4 patients (0.8%) were intermediate and poor metabolisers, respectively. Of these patients, 12 intermediate and 4 poor TPMT metabolisers had been prescribed tioguanine in varying doses. In one poor TPMT metaboliser, tioguanine 10 mg/day induced delayed pancytopenia. In general, reduced tioguanine dosages of 5 mg/day for intermediate TPMT metabolisers, and 10 mg two-weekly for poor TPMT metabolisers, resulted in a safe, long-term treatment strategy. Diminished or absent TPMT enzyme activity was related with a pharmacokinetic shift of tioguanine metabolism which is associated with relatively late-occurring myelotoxicity in patients on standard tioguanine dose. However, in strongly reduced dose regimens with strict therapeutic drug and safety monitoring, tioguanine treatment remained a safe and effective option in IBD patients with dysfunctional TPMT.
- Published
- 2023
- Full Text
- View/download PDF
34. Coronectomy of mandibular third molars with dental pathology: a prospective cohort study of 121 molars.
- Author
-
van Bodegraven, Arjan, Simons, Rashida N., Tuk, Jacco G., de Lange, Jan, and Lindeboom, Jerome A. H.
- Abstract
Purpose: Coronectomy is a valuable treatment proven safe for non-pathological mandibular third molars with an increased risk of inferior alveolar nerve injury. Coronectomy may also be useful for mandibular third molars with dentigerous cysts and caries, but this is not commonly performed due to the lack of well-designed, evidence-based studies. Here, we aim to investigate the safety of coronectomy for mandibular third molars with caries and dentigerous cysts. Methods: One hundred fifteen patients with an impacted mandibular third molar with a dentigerous cyst or caries underwent coronectomy or complete removal and received follow-up with clinical and radiographical examinations. We statistically compared the presence of postoperative complications after coronectomy versus complete removal. Results: Data from 121 molars were available for analysis. The results revealed no significant difference in the occurrence of postoperative complications (including persistent pain, inferior alveolar nerve injury, infection, alveolar osteitis, excessive bleeding, and the need for retreatment) between coronectomy and complete removal. Additionally, the incidence of postoperative complications was not related to any analyzed patient- or molar-related factors, including age, gender, health status, smoking, caries, dentigerous cyst extent, and impaction degree. Conclusion: For pathological impacted mandibular third molars with dentigerous cysts and caries, coronectomy exhibited both short-term and long-term safety, showing no significant difference in postoperative complications compared to total removal. Our results suggest that coronectomy can be indicated for pathological mandibular third molars with proximity to the inferior alveolar nerve. Trial registration number: Not applicable. [ABSTRACT FROM AUTHOR]
- Published
- 2025
- Full Text
- View/download PDF
35. Predictive algorithm for thiopurine-induced hepatotoxicity in IBD patients
- Author
-
van Moorsel, Sofia AW, Deben, Debbie S, Creemers, Rob H, Winkens, Bjorn, Bus, Paul, Pierik, Marieke J, Simsek, Melek, de Boer, Nanne KH, van Bodegraven, Adriaan A, and Wong, Dennis R
- Published
- 2022
- Full Text
- View/download PDF
36. Anterior knee pain and functional outcome following different surgical techniques for tibial nailing: a systematic review
- Author
-
Leliveld, Mandala S., Verhofstad, Michael H. J., Van Bodegraven, Eduard, Van Haaren, Jules, and Van Lieshout, Esther M. M.
- Published
- 2021
- Full Text
- View/download PDF
37. Impact of the COVID-19 pandemic on incidence and severity of acute appendicitis: a comparison between 2019 and 2020
- Author
-
Jochem C. G. Scheijmans, Alexander B. J. Borgstein, Carl A. J. Puylaert, Wouter J. Bom, Said Bachiri, Eduard A. van Bodegraven, Amarins T. A. Brandsma, Floor M. ter Brugge, Steve M. M. de Castro, Roy Couvreur, Lotte C. Franken, Marcia P. Gaspersz, Michelle R. de Graaff, Hannah Groenen, Suzanne C. Kleipool, Toon J. L. Kuypers, Milou H. Martens, David M. Mens, Ricardo G. Orsini, Nando J. M. M. Reneerkens, Thomas Schok, Wouter J. A. Sedee, Shahzad Tavakoli Rad, José H. Volders, Pepijn D. Weeder, Jan M. Prins, Hester A. Gietema, Jaap Stoker, Suzanne S. Gisbertz, Marc G. H. Besselink, Marja A. Boermeester, and the SCOUT Collaboarative Study group
- Subjects
Acute appendicitis ,COVID-19 pandemic ,Complicated appendicitis ,Special situations and conditions ,RC952-1245 ,Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Abstract
Abstract Background During the COVID-19 pandemic, a decrease in the number of patients presenting with acute appendicitis was observed. It is unclear whether this caused a shift towards more complicated cases of acute appendicitis. We compared a cohort of patients diagnosed with acute appendicitis during the 2020 COVID-19 pandemic with a 2019 control cohort. Methods We retrospectively included consecutive adult patients in 21 hospitals presenting with acute appendicitis in a COVID-19 pandemic cohort (March 15 – April 30, 2020) and a control cohort (March 15 – April 30, 2019). Primary outcome was the proportion of complicated appendicitis. Secondary outcomes included prehospital delay, appendicitis severity, and postoperative complication rates. Results The COVID-19 pandemic cohort comprised 607 patients vs. 642 patients in the control cohort. During the COVID-19 pandemic, a higher proportion of complicated appendicitis was seen (46.9% vs. 38.5%; p = 0.003). More patients had symptoms exceeding 24 h (61.1% vs. 56.2%, respectively, p = 0.048). After correction for prehospital delay, presentation during the first wave of the COVID-19 pandemic was still associated with a higher rate of complicated appendicitis. Patients presenting > 24 h after onset of symptoms during the COVID-19 pandemic were older (median 45 vs. 37 years; p = 0.001) and had more postoperative complications (15.3% vs. 6.7%; p = 0.002). Conclusions Although the incidence of acute appendicitis was slightly lower during the first wave of the 2020 COVID-19 pandemic, more patients presented with a delay and with complicated appendicitis than in a corresponding period in 2019. Spontaneous resolution of mild appendicitis may have contributed to the increased proportion of patients with complicated appendicitis. Late presenting patients were older and experienced more postoperative complications compared to the control cohort.
- Published
- 2021
- Full Text
- View/download PDF
38. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial
- Author
-
Hart, Ailsa, Warusavitarne, Janindra, Van Bodegraven, Ad A., Brink, Menno A., Consten, Esther C.J., Van Wagensveld, Bart A., Rijk, Marno C.M., Crolla, Rogier M.P.H., Noomen, Casper G., Houdijk, Alexander P.J., Mallant, Rosalie C., Boom, Maarten, Marsman, Willem A., Stockmann, Hein B., De Groof, A. Jeroen, Bruin, Karlien, Maring, John, van Ditzhuijsen, Theo, Prins, Hubert, van den Brande, Jan, Kingma, Paul, van Geloven, Anna, de Boer, Nanne, van der Peet, Donald, Jansen, Jeroen, Gerhards, Michael, van der Woude, Janneke, Schouten, Ruud, Oldenburg, Bas, van Hillegersberg, Richard, West, Rachel, Mannaerts, Guido, Spanier, Marcel, Spillenaar Bilgen, Ernst Jan, Lieverse, Rob, van der Zaag, Edwin, Depla, Annekatrien, van de Laar, Arnold, Bolwerk, Clemens, Brouwer, Hans, Mahmmod, Nofel, Hazebroek, Eric, Vecht, Juda, Pierik, Robert, Dijkstra, Gerard, Hofker, Sijbrand, Uiterwaal, Tessa, Eijsbouts, Quirijn, Oostenbrug, Liekele, Sosef, Meindert, Cahen, Djuna, van der Werff, Sjoerd, Marinelli, Andreas, Peters, Job, Cense, Huib, Talstra, Nynke, Morar, Pritesh, Stevens, Toer W, Haasnoot, Maria L, D'Haens, Geert R, Buskens, Christianne J, de Groof, E Joline, Eshuis, Emma J, Gardenbroek, Tjibbe J, Mol, Bregje, Stokkers, Pieter C F, Bemelman, Willem A, and Ponsioen, Cyriel Y
- Published
- 2020
- Full Text
- View/download PDF
39. Intermediate filaments against actomyosin: the david and goliath of cell migration
- Author
-
van Bodegraven, Emma J. and Etienne-Manneville, Sandrine
- Published
- 2020
- Full Text
- View/download PDF
40. Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial
- Author
-
de Jong, Marin J., Boonen, Annelies, van der Meulen-de Jong, Andrea E., Romberg-Camps, Mariëlle J., van Bodegraven, Ad A., Mahmmod, Nofel, Markus, Tineke, Dijkstra, Gerard, Winkens, Bjorn, van Tubergen, Astrid, Masclee, Ad, Jonkers, Daisy M., and Pierik, Marie J.
- Published
- 2020
- Full Text
- View/download PDF
41. Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study
- Author
-
Merve Sivridaş, Rob H. Creemers, Dennis R. Wong, Paul J. Boekema, Tessa E. H. Römkens, Lennard P. L. Gilissen, Adriaan A. van Bodegraven, Floris C. Loeff, Theo Rispens, and Luc J. J. Derijks
- Subjects
vedolizumab ,trough level ,therapeutic drug monitoring ,maintenance ,IBD ,ulcerative colitis ,Pharmacy and materia medica ,RS1-441 - Abstract
There are limited data on therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) patients treated with vedolizumab (VDZ). Although an exposure–response relation has been demonstrated in the post-induction phase, this relationship is more uncertain in the maintenance phase of treatment. The aim of our study was to determine whether there is an association between VDZ trough concentration and clinical and biochemical remission in the maintenance phase. A prospective, observational multicenter study has been performed on patients with IBD on VDZ in the maintenance treatment (≥14 weeks). Patient demographics, biomarkers, and VDZ serum trough concentrations were collected. Clinical disease activity was scored by the Harvey Bradshaw Index (HBI) for Crohn’s disease (CD) and the Simple Clinical Colitis Activity Index (SCCAI) for ulcerative colitis (UC). Clinical remission was determined as HBI < 5 and SCCAI < 3. Biochemical remission was defined as fecal calprotectin p = 0.019). In this population, higher trough VDZ concentrations were associated with biochemical remission but not with clinical remission.
- Published
- 2023
- Full Text
- View/download PDF
42. Deep Learning with Northern Australian Savanna Tree Species: A Novel Dataset.
- Author
-
Andrew J. Jansen, Jaylen D. Nicholson, Andrew J. Esparon, Timothy G. Whiteside, Michael Welch, Matthew Tunstill, Harinandanan Paramjyothi, Varma Gadhiraju, Steve van Bodegraven, and Renée E. Bartolo
- Published
- 2023
- Full Text
- View/download PDF
43. Vulvar and vaginal neoplasia in women with inflammatory bowel disease
- Author
-
Löwenberg, M., Bodelier, A., Verbeek, W.H., Schoon, E., Witteman, E.M., Herwaarden, M.A., Van Der Woude, C.J., Lutgens, M., Kouw, E., Van Der Veek, P.J., van der Hulst, R.W., Sipkema, H., Nissen, L.H.C., Bus, P.J., van der Meulen, A.E., De Bruijne, F.H., van der Waaij, L.A., Noomen, C.G., Jharap, B., Schmittgens, S., Jansen, J.M., Hoentjen, F., Lammertink, M.H.A., Houben, G.M.P., Minderhoud, I.M., Dijkstra, G., Oldenburg, B., Sikkens, M.S.G., Van Tuyl, S.A., van Bodegraven, A.A., Rouvroye, Maxine D., Tack, Greetje J., Mom, Constantijne H., Lissenberg-Witte, Birgit I., Pierik, Marieke J., Neefjes-Borst, E. Andra, and de Boer, Nanne K.H.
- Published
- 2020
- Full Text
- View/download PDF
44. Minimally invasive robot-assisted and laparoscopic distal pancreatectomy in a pan-European registry a retrospective cohort study
- Author
-
MS CGO, Cancer, van Bodegraven, Eduard A., van Ramshorst, Tess M.E., Bratlie, Svein O., Kokkola, Arto, Sparrelid, Ernesto, Björnsson, Bergthor, Kleive, Dyre, Burgdorf, Stefan K., Dokmak, Safi, Groot Koerkamp, Bas, Cabús, Santiago Sánchez, Molenaar, I. Quintus, Boggi, Ugo, Busch, Olivier R., Petrič, Miha, Roeyen, Geert, Hackert, Thilo, Lips, Daan J., D'Hondt, Mathieu, Coolsen, Mariëlle M.E., Ferrari, Giovanni, Tingstedt, Bobby, Serrablo, Alejandro, Gaujoux, Sebastien, Ramera, Marco, Khatkov, Igor, Ausania, Fabio, Souche, Regis, Festen, Sebastiaan, Berrevoet, Frederik, Keck, Tobias, Sutcliffe, Robert P., Pando, Elizabeth, de Wilde, Roeland F., Aussilhou, Beatrice, Krohn, Paul S., Edwin, Bjørn, Sandström, Per, Gilg, Stefan, Seppänen, Hanna, Vilhav, Caroline, Abu Hilal, Mohammad, Besselink, Marc G., European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS), MS CGO, Cancer, van Bodegraven, Eduard A., van Ramshorst, Tess M.E., Bratlie, Svein O., Kokkola, Arto, Sparrelid, Ernesto, Björnsson, Bergthor, Kleive, Dyre, Burgdorf, Stefan K., Dokmak, Safi, Groot Koerkamp, Bas, Cabús, Santiago Sánchez, Molenaar, I. Quintus, Boggi, Ugo, Busch, Olivier R., Petrič, Miha, Roeyen, Geert, Hackert, Thilo, Lips, Daan J., D'Hondt, Mathieu, Coolsen, Mariëlle M.E., Ferrari, Giovanni, Tingstedt, Bobby, Serrablo, Alejandro, Gaujoux, Sebastien, Ramera, Marco, Khatkov, Igor, Ausania, Fabio, Souche, Regis, Festen, Sebastiaan, Berrevoet, Frederik, Keck, Tobias, Sutcliffe, Robert P., Pando, Elizabeth, de Wilde, Roeland F., Aussilhou, Beatrice, Krohn, Paul S., Edwin, Bjørn, Sandström, Per, Gilg, Stefan, Seppänen, Hanna, Vilhav, Caroline, Abu Hilal, Mohammad, Besselink, Marc G., and European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS)
- Published
- 2024
45. A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease:Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial
- Author
-
van Linschoten, Reinier C.A., Jansen, Fenna M., Pauwels, Renske W.M., Smits, Lisa J.T., Atsma, Femke, Kievit, Wietske, de Jong, Dirk J., de Vries, Annemarie C., Boekema, Paul J., West, Rachel L., Bodelier, Alexander G.L., Gisbertz, Ingrid A.M., Wolfhagen, Frank H.J., Römkens, Tessa E.H., Lutgens, Maurice W.M.D., van Bodegraven, Adriaan A., Oldenburg, Bas, Pierik, Marieke J., Russel, Maurice G.V.M., de Boer, Nanne K., Mallant-Hent, Rosalie C., ter Borg, Pieter C.J., van der Meulen-de Jong, Andrea E., Jansen, Jeroen M., Jansen, Sita V., Tan, Adrianus C.I.T.L., van der Woude, C. Janneke, Hoentjen, Frank, van Linschoten, Reinier C.A., Jansen, Fenna M., Pauwels, Renske W.M., Smits, Lisa J.T., Atsma, Femke, Kievit, Wietske, de Jong, Dirk J., de Vries, Annemarie C., Boekema, Paul J., West, Rachel L., Bodelier, Alexander G.L., Gisbertz, Ingrid A.M., Wolfhagen, Frank H.J., Römkens, Tessa E.H., Lutgens, Maurice W.M.D., van Bodegraven, Adriaan A., Oldenburg, Bas, Pierik, Marieke J., Russel, Maurice G.V.M., de Boer, Nanne K., Mallant-Hent, Rosalie C., ter Borg, Pieter C.J., van der Meulen-de Jong, Andrea E., Jansen, Jeroen M., Jansen, Sita V., Tan, Adrianus C.I.T.L., van der Woude, C. Janneke, and Hoentjen, Frank
- Abstract
Background: In the pragmatic open-label randomised controlled non-inferiority LADI trial we showed that increasing adalimumab (ADA) dose intervals was non-inferior to conventional dosing for persistent flares in patients with Crohn’s disease (CD) in clinical and biochemical remission. Aims: To develop a prediction model to identify patients who can successfully increase their ADA dose interval based on secondary analysis of trial data. Methods: Patients in the intervention group of the LADI trial increased ADA intervals to 3 and then to 4 weeks. The dose interval increase was defined as successful when patients had no persistent flare (> 8 weeks), no intervention-related severe adverse events, no rescue medication use during the study, and were on an increased dose interval while in clinical and biochemical remission at week 48. Prediction models were based on logistic regression with relaxed LASSO. Models were internally validated using bootstrap optimism correction. Results: We included 109 patients, of which 60.6% successfully increased their dose interval. Patients that were active smokers (odds ratio [OR] 0.90), had previous CD-related intra-abdominal surgeries (OR 0.85), proximal small bowel disease (OR 0.92), an increased Harvey-Bradshaw Index (OR 0.99) or increased faecal calprotectin (OR 0.997) were less likely to successfully increase their dose interval. The model had fair discriminative ability (AUC = 0.63) and net benefit analysis showed that the model could be used to select patients who could increase their dose interval. Conclusion: The final prediction model seems promising to select patients who could successfully increase their ADA dose interval. The model should be validated externally before it may be applied in clinical practice. Clinical Trial Registration Number: ClinicalTrials.gov, number NCT03172377.
- Published
- 2024
46. GFAP-isoforms in the nervous system: Understanding the need for diversity
- Author
-
TN groep Hol, Brain, Translational Neuroscience, Cancer, de Reus, Alexandra J E M, Basak, Onur, Dykstra, Werner, van Asperen, Jessy V, van Bodegraven, Emma J, Hol, Elly M, TN groep Hol, Brain, Translational Neuroscience, Cancer, de Reus, Alexandra J E M, Basak, Onur, Dykstra, Werner, van Asperen, Jessy V, van Bodegraven, Emma J, and Hol, Elly M
- Published
- 2024
47. Recycling of solar panels. Comparison of scenarios for a more circular and safe product chain
- Author
-
Lijzen, JPA, Heens, F, Dekker, E, van Bodegraven, M, Hof, M, Lijzen, JPA, Heens, F, Dekker, E, van Bodegraven, M, and Hof, M
- Abstract
RIVM rapport:Nederland streeft naar een circulaire economie in 2050. Een onderdeel daarvan is grondstoffen en materialen recyclen, zoals zonnepanelen. Op dit moment worden grondstoffen uit zonnepanelen na gebruik nog niet teruggewonnen. Naar verwachting zullen over ruim vijf jaar de eerste grote hoeveelheden zonnepanelen als afval vrijkomen. Het is belangrijk om hierop voorbereid te zijn en ze veilig en duurzaam te kunnen recyclen. Er zijn verschillende technologieën in ontwikkeling om zonnepanelen te recyclen. Het RIVM heeft vier mogelijkheden uitgewerkt om het glas, de zonnecellen en het achterblad ervan te recyclen. De teruggewonnen materialen uit zonnepanelen kunnen opnieuw worden gebruikt als grondstof voor verschillende toepassingen. In dit onderzoek is gekeken is welke mogelijkheden in de praktijk uitvoerbaar lijken en hoe milieuvriendelijk ze zijn. De vier varianten zijn vergeleken met de huidige situatie (de basisvariant). Daarin wordt vermalen glas van zonnepanelen als schuurmiddel in de metaalindustrie gebruikt en daarna verwerkt in bijvoorbeeld funderingsmateriaal voor wegen. Uit de analyse blijkt dat alle vier de varianten meer circulair en milieuvriendelijker zijn dan de basisvariant. Het energiegebruik verschilt iets per variant maar is veel lager dan dat van de basisvariant. Dat komt onder andere doordat het meer energie kost om nieuwe grondstoffen voor zonnepanelen te maken dan met gerecyclede grondstoffen te werken. Het meest circulair is de variant waarin van glas nieuw glas voor zonnepanelen wordt gemaakt. In deze variant kan ook de grondstof silicium worden herwonnen voor nieuwe zonnecellen. Dit is technologisch ingewikkeld maar wel mogelijk. Bij de recycling is aandacht nodig voor gevaarlijke stoffen in zonnepanelen: lood, antimoon en PFAS. Lood zit in het soldeermateriaal en antimoon zorgt voor de helderheid van het glas. PFAS zitten als fluorpolymeren in het achterblad van zonnepanelen, waardoor bij verbranding PFAS kunnen vrijkomen. De manier van recycle, The Netherlands has set a target of a circular economy by 2050. This entails that raw and manufactured materials, such as those in solar panels, are recycled. Currently, no raw materials are recovered from End-of-Life solar panels. It is expected that the first generation of solar panels will start to be taken out of use in large numbers in five years' time. It is important to be prepared for this and to recycle the panels safely and sustainably. Various technologies to recycle solar panels are being developed. RIVM has detailed four options for recycling the glass, solar cells and back sheets of solar panels. The materials recovered from solar panels can be reused as raw materials for various applications. For this study, we looked into which recycling options appear to be feasible in practice and how environmentally friendly they are. We compared these four options to the current situation (the baseline), in which the solar panels are shredded, the glass is crushed and used as an abrasive medium in the metal industry, and the remainder is then processed for various applications, such as for road bases. Our analysis shows that all four options are more circular and environmentally friendly than the baseline. Energy consumption differs for each option, but is much lower than for the baseline. This is due to various factors, including the fact that it costs more energy to process new raw materials into solar panels than to work with recycled raw materials. The option whereby glass is recycled into new glass for solar panels is the most circular one. In this case, the raw material silicon can also be recycled for use in new solar panels. This is technologically complex, but feasible. In the recycling process, attention must be paid to hazardous substances in solar panels: lead, antimony and per- and polyfluoroalkyl substances (PFAS). Lead is contained in soldering materials and antimony is added to make the glass brighter. The backsheets of solar panels contain PFAS a
- Published
- 2024
48. Minimally invasive robot-assisted and laparoscopic distal pancreatectomy in a pan-European registry a retrospective cohort study
- Author
-
van Bodegraven, Eduard A, van Ramshorst, Tess M E, Bratlie, Svein O, Kokkola, Arto, Sparrelid, Ernesto, Björnsson, Bergthor, Kleive, Dyre, Burgdorf, Stefan K, Dokmak, Safi, Groot Koerkamp, Bas, Cabús, Santiago Sánchez, Molenaar, I Quintus, Boggi, Ugo, Busch, Olivier R, Petrič, Miha, Roeyen, Geert, Hackert, Thilo, Lips, Daan J, D'Hondt, Mathieu, Coolsen, Mariëlle M E, Ferrari, Giovanni, Tingstedt, Bobby, Serrablo, Alejandro, Gaujoux, Sebastien, Ramera, Marco, Khatkov, Igor, Ausania, Fabio, Souche, Regis, Festen, Sebastiaan, Berrevoet, Frederik, Keck, Tobias, Sutcliffe, Robert P, Pando, Elizabeth, de Wilde, Roeland F, Aussilhou, Beatrice, Krohn, Paul S, Edwin, Bjørn, Sandström, Per, Gilg, Stefan, Seppänen, Hanna, Vilhav, Caroline, Abu Hilal, Mohammad, Besselink, Marc G, van Bodegraven, Eduard A, van Ramshorst, Tess M E, Bratlie, Svein O, Kokkola, Arto, Sparrelid, Ernesto, Björnsson, Bergthor, Kleive, Dyre, Burgdorf, Stefan K, Dokmak, Safi, Groot Koerkamp, Bas, Cabús, Santiago Sánchez, Molenaar, I Quintus, Boggi, Ugo, Busch, Olivier R, Petrič, Miha, Roeyen, Geert, Hackert, Thilo, Lips, Daan J, D'Hondt, Mathieu, Coolsen, Mariëlle M E, Ferrari, Giovanni, Tingstedt, Bobby, Serrablo, Alejandro, Gaujoux, Sebastien, Ramera, Marco, Khatkov, Igor, Ausania, Fabio, Souche, Regis, Festen, Sebastiaan, Berrevoet, Frederik, Keck, Tobias, Sutcliffe, Robert P, Pando, Elizabeth, de Wilde, Roeland F, Aussilhou, Beatrice, Krohn, Paul S, Edwin, Bjørn, Sandström, Per, Gilg, Stefan, Seppänen, Hanna, Vilhav, Caroline, Abu Hilal, Mohammad, and Besselink, Marc G
- Abstract
BACKGROUND: International guidelines recommend monitoring the use and outcome of minimally invasive pancreatic surgery (MIPS). However, data from prospective international audits on minimally invasive distal pancreatectomy (MIDP) are lacking. This study examined the use and outcome of robot-assisted (RDP) and laparoscopic (LDP) distal pancreatectomy in the E-MIPS registry. PATIENTS AND METHODS: Post-hoc analysis in a prospective audit on MIPS, including consecutive patients undergoing MIDP in 83 centers from 19 European countries (01-01-2019/31-12-2021). Primary outcomes included intraoperative events (grade 1: excessive blood loss, grade 2: conversion/change in operation, grade 3: intraoperative death), major morbidity, and in-hospital/30-day mortality. Multivariable logistic regression analyses identified high-risk groups for intraoperative events. RDP and LDP were compared in the total cohort and high-risk groups. RESULTS: Overall, 1672 patients undergoing MIDP were included; 606 (36.2%) RDP and 1066 (63.8%) LDP. The annual use of RDP increased from 30.5% to 42.6% ( P <0.001). RDP was associated with fewer grade 2 intraoperative events compared with LDP (9.6% vs. 16.8%, P <0.001), with longer operating time (238 vs. 201 min, P <0.001). No significant differences were observed between RDP and LDP regarding major morbidity (23.4% vs. 25.9%, P =0.264) and in-hospital/30-day mortality (0.3% vs. 0.8%, P =0.344). Three high-risk groups were identified; BMI greater than 25 kg/m 2 , previous abdominal surgery, and vascular involvement. In each group, RDP was associated with fewer conversions and longer operative times. CONCLUSION: This European registry-based study demonstrated favorable outcomes for MIDP, with mortality rates below 1%. LDP remains the predominant approach, whereas the use of RDP is increasing. RDP was associated with fewer conversions and longer operative time, including in high-risk subgroups. Future randomized trials should confirm these f
- Published
- 2024
49. Perspective on skeletal health in inflammatory bowel disease
- Author
-
van Bodegraven, A. A. and Bravenboer, N.
- Published
- 2020
- Full Text
- View/download PDF
50. Exocrine pancreatic and enterocyte function in patients with advanced pancreatic cancer
- Author
-
Witvliet-van Nierop, J.E., de van der Schueren, M.A.E., Scheffer, H.J., Vroomen, L.G., Meijerink, M.R., van Bodegraven, A.A., and Wierdsma, N.J.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.